19934-26-0

Usage

Uses

Used in Pharmaceutical Industry:
(E)-N-((5-(4-nitrophenyl)furan-2-yl)methylene)benzohydrazide is used as a potential therapeutic agent for its anti-inflammatory and anti-cancer properties. (E)-N-((5-(4-nitrophenyl)furan-2-yl)methylene)benzohydrazide has shown to inhibit the growth of cancer cells, making it a promising candidate for the development of new cancer treatments.
Used in Research and Development:
BNPFH is used as a subject of study in the field of medicinal chemistry due to its unique chemical structure and potential biological activities. Researchers are interested in exploring its properties further to understand its full potential in the development of new drugs and therapies.
Used in Biomedical Imaging:
(E)-N-((5-(4-nitrophenyl)furan-2-yl)methylene)benzohydrazide is used as a potential fluorescent probe in biological imaging. Its ability to emit fluorescence under certain conditions makes it a candidate for use in imaging techniques that require the visualization of specific biological processes or structures.

Upstream product

• 7147-77-5 5-(4-nitrophenyl)-2-furaldehyde 
• 613-94-5 benzoic acid hydrazide 

Relevant academic research and scientific papers

Comparative study of microwave assisted and conventional synthesis of furfuraldehyde based hydrazone derivatives and their metal complexes with biological evaluation

A series of acyl hydrazone derivatives were synthesized by the condensation of different hydrazides (benzohydrazide, isoniazid, nicotinic acid hydrazide and salicylhydrazide) and 5-(4′-nitrophenyl) furan-2-carbaldehyde. These hydrazones were subjected for metal complexation to yield copper(II) and nickel(II) complexes using conventional and microwave irradiation method. The microwave method was found to be successful with nearly the same or higher yields and shorter reaction time. The synthesized compounds were characterized by EIMS, CHN analysis, FTIR and NMR spectroscopy. All the synthesized compounds were screened for their antibacterial and antioxidant activities.

Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator

The phenylhydrazone RDR-1 is endowed with moderate activity as F508del-CFTR corrector; nevertheless, its simple structure enables stimulating developments in this class of correctors. Therefore, we synthesized a number of phenylhydrazones 3 by reacting phenylhydrazine derivatives 1 with furfural derivatives 2. By the same reaction, also the pyridine derivatives 4, the thiophene derivatives 5, and the hydrazides 6 and 7 were prepared. All compounds were tested as F508del-CFTR correctors in the cystic fibrosis (CF) bronchial epithelial cell line CFBE41o-, using corr-4a and VX-809 as controls. Some of the tested compounds emerged as interesting F508del-CFTR correctors at 20 μM (3c) and 2 μM (5d). 3c and 5d administered together with VX-809 produced a satisfactory additivity of action. When the structure of 5d was overlapped with RDR-1 and five other established correctors, a shared central design was clearly visible. This fact may be of interest in the search for new F508del-CFTR correctors. Starting from RDR-1, a known F508del-CFTR corrector, some phenylhydrazones were synthesized. Two new compounds (3c and 5d) showed encouraging activity and, when administered together with the corrector VX-809, gave an additivity of action. Overlapping the molecular design of 5d with RDR-1 and other known correctors revealed a common structural moiety, which may help in the search for new drugs against cystic fibrosis.